AC Immune SA (ACIU) Reports Q1 Loss of $0.15 Apr 30, 2026 07:10AM
Leerink Partners on AC Immune SA (ACIU): Lilly deal amendment is 'great news,' validates platform Apr 7, 2026 02:44PM
AC Immune amends Lilly collaboration for tau drug development Apr 7, 2026 07:01AM
H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU) Mar 16, 2026 06:51AM
Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial' Mar 13, 2026 09:05AM


Nov 4, 2025 08:07AM AC Immune SA (ACIU) Tops Q3 EPS by 3c
Oct 24, 2025 08:50AM AC Immune publishes TDP-43 PET tracer data in Nature Communications
May 1, 2025 07:25AM AC Immune SA (ACIU) PT Lowered to $12 at H.C. Wainwright
Apr 2, 2025 06:26AM AC Immune SA (ACIU) Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
Dec 10, 2024 07:01AM AC Immune SA (ACIU) Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Nov 14, 2024 07:00AM AC Immune SA (ACIU) Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056
Sep 18, 2024 06:41AM H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)
Sep 17, 2024 07:00AM AC Immune SA (ACIU) Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
Aug 28, 2024 09:01AM AC Immune's (ACIU) PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
Jul 31, 2024 08:32AM AC Immune SA (ACIU) Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
Jul 25, 2024 07:00AM AC Immune's (ACIU) ACI-35.030 Granted FDA Fast Track Designation for Alzheimer’s Disease